Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 1.00 |
| ▸ | PDE4A | P27815 | 9/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 9/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 9/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 9/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 14/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27396492 | 1.00 | ADORA2A (1.00) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7217322 | 0.98 | ADORA2A (0.97) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4423680 | 0.87 | ADORA2B (1.00) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6233166 | 0.84 | ADORA2B (1.00) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27395394 | 0.84 | ADORA2B (1.00) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5515444 | 0.83 | ADORA2A (0.71) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27586849 | 0.83 | ADORA2A (0.71) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7455767 | 0.83 | ADORA2A (0.71) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1892011 | 0.83 | ADORA2B (0.92) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL60158 | 0.83 | ADORA2A (0.70) | ADORA2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3946353-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ADCY5-RELATED DYSKINESIA | ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS (FR) | 2022-02-09 | — | — | EP | claimed |
| WO-2020193567-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ADCY5-RELATED DYSKINESIA | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2020-10-01 | — | — | WO | claimed |
| US-5700369-A | Process for adsorboaggregational flotation of Carlin type natural gold ore dressing | GUANGZHOU INSTITUTE OF GEOCHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 1997-12-23 | — | — | US | claimed |
| US-5470579-A | Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation | LVMH, RECHERCHE (FR) | 1995-11-28 | — | — | US | claimed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | claimed |
| CN-122029936-A | Light-emitting element, display device, and method for manufacturing light-emitting element | 夏普显示科技株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-12559458-B2 | Co-crystals or salts of psilocin and methods of treatment therewith | Reset Pharmaceuticals, Inc. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4486448-A1 | CO-CRYSTALS OR SALTS COMPRISING PSILOCIN | Reset Pharmaceuticals, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240383849-A1 | CO-CRYSTAL OR SALT | Reset Pharmaceuticals, Inc. | 2024-11-21 | — | — | US | disclosed |
| CN-118871423-A | Co-crystals or salts comprising xylometacin | 雷塞特制药股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-115745998-B | Method for synthesizing gouache mushroom and analogue thereof by photocatalysis | 新乡学院 | 2024-10-22 | — | — | CN | disclosed |
| US-12060328-B2 | Co-crystals or salts of psilocybin and methods of treatment therewith | Reset Pharmaceuticals, Inc. (US) | 2024-08-13 | — | — | US | disclosed |
| EP-0528951-A4 | HUMANIZED CDR-GRAFTED ANTI-ICAM-1 ANTIBODIES, METHODS OF PREPARATION AND USAGE THEREOF | — | 1993-05-26 | — | — | EP | disclosed |
| EP-0528951-A1 | HUMANIZED CDR-GRAFTED ANTI-ICAM-1 ANTIBODIES, METHODS OF PREPARATION AND USAGE THEREOF | CELLTECH LIMITED (GB) | 1993-03-03 | — | — | EP | disclosed |
| EP-0502043-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR. | LVMH RECH (FR) | 1992-09-09 | — | — | EP | disclosed |
| WO-1992007566-A2 | ANTIFUNGAL ACTIVITY OF AND PREVENTION OF DRUG INDUCED NEPHROTOXICITY BY METHYLXANTHINE ANALOGUES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-05-14 | — | — | WO | disclosed |
| EP-0480934-A1 | A SLIMMING PHARMACEUTICAL COMPOSITION. | DAK LAB AS (DK) | 1992-04-22 | — | — | EP | disclosed |
| WO-1991016927-A1 | HUMANIZED CDR-GRAFTED ANTI-ICAM-1 ANTIBODIES, METHODS OF PREPARATION AND USAGE THEREOF | CELLTECH LIMITED (GB) | 1991-11-14 | — | — | WO | disclosed |
| WO-1991007945-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECHERCHE (FR) | 1991-06-13 | — | — | WO | disclosed |
| WO-1991000730-A1 | A SLIMMING PHARMACEUTICAL COMPOSITION | DAK-LABORATORIET A/S (DK) | 1991-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383849-A1 | CO-CRYSTAL OR SALT | SLC6A3, SLC6A2, OPRK1 | ADORA2A 1052/4885PDE4A 255/4885PDE4B 190/4885 |
| US-12060328-B2 | Co-crystals or salts of psilocybin and methods of treatment therewith | SLC6A3, SLC6A2, HTR2B | ADORA2A 387/4885PDE4A 160/4885PDE4B 100/4885 |
| US-12559458-B2 | Co-crystals or salts of psilocin and methods of treatment therewith | SLC6A2, SLC6A4, SLC6A3 | ADORA2A 232/4885PDE4A 192/4885PDE4B 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.